ACTH: The forgotten therapy

Seminars in Immunology
Trinidad Montero-Melendez

Abstract

Although anti-inflammatory drugs are among the most common class of marketed drugs, chronic inflammatory conditions such as rheumatoid arthritis, multiple sclerosis or inflammatory bowel disease still represent unmet needs. New first-in-class drugs might be discovered in the future but the repurpose and further development of old drugs also offers promise for these conditions. This is the case of the melanocortin adrenocorticotropin hormone, ACTH, used in patients since 1952 but regarded as the last therapeutic option when other medications, such as glucocorticoids, cannot be used. Better understanding on its physiological and pharmacological mechanisms of actions and new insights on melanocortin receptors biology have revived the interest on rescuing this old and effective drug. ACTH does not only induce cortisol production, as previously assumed, but it also exerts anti-inflammatory actions by targeting melanocortin receptors present on immune cells. The endogenous agonists for these receptors (ACTH, α-, β-, and γ-melanocyte stimulating hormones), are also produced locally by immune cells, indicating the existence of an endogenous anti-inflammatory tissue-protective circuit involving the melanocortin system. These findings su...Continue Reading

References

Oct 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·T K SawyerM E Hadley
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·R A StarJ M Lipton
Mar 1, 1997·Molecular Endocrinology·Y K YangI Gantz
Feb 1, 2000·Trends in Endocrinology and Metabolism : TEM·H Krude, A Grüters
Jan 6, 2001·Molecular Endocrinology·W A NijenhuisR A Adan
Oct 24, 2002·Melanoma Research·R A Sturm
Oct 10, 2003·The Journal of Pharmacology and Experimental Therapeutics·Zhenhai GaoDavid Duhl
Nov 20, 2003·Journal of Cell Science·Wesley K KroezeBryan L Roth
Mar 6, 2004·Pharmacological Reviews·Anna CataniaJames M Lipton
May 12, 2004·Nature Reviews. Drug Discovery·Derek W GilroyAdriano G Rossi
Jul 15, 2004·Pigment Cell Research·Jesús Sánchez-MásCelia Jiménez-Cervantes
Jul 28, 2004·Anesthesiology·Edwin B LiemDaniel I Sessler
Dec 8, 2004·Biochemical and Biophysical Research Communications·Ilona MandrikaJarl Wikberg
Mar 4, 2005·The Journal of Pharmacology and Experimental Therapeutics·Sarah A NickollsRich A Maki
Nov 11, 2005·Pigment Cell Research·José C García-BorrónCelia Jiménez-Cervantes
Jan 31, 2006·Current Opinion in Structural Biology·Andrew L HopkinsJohn P Overington
Feb 21, 2006·Pharmacology & Therapeutics·Stephen J Getting
Apr 4, 2006·The Journal of Surgical Research·Erika A NewmanMichael W Mulholland
Oct 3, 2006·Annual Review of Pharmacology and Toxicology·Lauren T MayArthur Christopoulos
Nov 2, 2006·Endocrine Reviews·Roger D Cone
Dec 26, 2006·Regulatory Peptides·Biaoxin ChaiMichael W Mulholland
Jan 20, 2007·The Journal of Investigative Dermatology·Hyun Jeong ParkDae Ho Cho
Feb 3, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Charles N SerhanJohn L Wallace
May 6, 2008·Nature Genetics·Ruth J F LoosKaren L Mohlke
Mar 23, 2010·Cell·Carl Nathan, Aihao Ding
Apr 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Mone ZaidiHarry C Blair
May 13, 2010·Journal of Molecular Endocrinology·Yewei XingWilliam E Rainey
Aug 13, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hetal B PatelMauro Perretti
May 3, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Charles N Serhan

❮ Previous
Next ❯

Citations

Mar 30, 2016·Nature Reviews. Drug Discovery·James N Fullerton, Derek W Gilroy
May 21, 2016·Frontiers in Immunology·Michelle A SugimotoMauro M Teixeira
May 21, 2016·Frontiers in Endocrinology·Rebecca DumbellHenrik Oster
Jun 16, 2016·Frontiers in Genetics·Erin M Wolf HorrellJohn A D'Orazio
Oct 20, 2015·Trends in Pharmacological Sciences·Mauro PerrettiTrinidad Montero-Melendez
Nov 18, 2016·Cellular and Molecular Life Sciences : CMLS·Trinidad Montero-MelendezMauro Perretti
Jan 6, 2017·Nature Reviews. Rheumatology·Mauro PerrettiLucy V Norling
Jan 27, 2018·International Journal of Molecular Sciences·Susanne Grässel, Dominique Muschter
Nov 16, 2017·Reproductive Sciences·Annelyn Torres-ReverónCaroline B Appleyard
Dec 15, 2017·Annals of the Rheumatic Diseases·Rohit AggarwalChester V Oddis
Feb 24, 2018·Annals of the Rheumatic Diseases·Rohit Aggarwal, Chester V Oddis
Apr 3, 2019·Clinical & Experimental Ophthalmology·Muhammad HassanQuan D Nguyen
Nov 15, 2019·Therapeutic Advances in Respiratory Disease·Ishveen ChopraGeorge J Wan
Feb 8, 2020·Advanced Healthcare Materials·Shasha WangLiming Nie
Aug 19, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mila F M MadeiraMauro Perretti
Mar 12, 2020·Rheumatology·Didem SayginRohit Aggarwal
Jul 14, 2020·Current Opinion in Pulmonary Medicine·Jelle R MiedemaPaolo Spagnolo
Apr 23, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wioletta SiemiradzkaFlorian Ryszka
Aug 15, 2017·Brain Sciences·Robert P Lisak, Joyce A Benjamins
Sep 7, 2017·Journal of Neuroscience Research·Joyce A BenjaminsRobert P Lisak
Aug 30, 2018·Frontiers in Pharmacology·Sara PatrunoTrinidad Montero-Melendez
Jun 19, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wioletta SiemiradzkaFlorian Ryszka
Jul 17, 2020·Frontiers in Molecular Neuroscience·Lorraine SieboldStephen Ashwal
Aug 9, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Alexander B CraneDavid S Chu
Feb 8, 2020·Nature Communications·Trinidad Montero-MelendezMauro Perretti
Aug 28, 2020·Frontiers in Pharmacology·Antonio RecchiutiMario Romano
Oct 28, 2019·Frontiers in Endocrinology·Wei WangYa-Xiong Tao
Dec 2, 2020·Nature Reviews. Rheumatology·Mauro Perretti
Jan 14, 2021·Cellular and Molecular Life Sciences : CMLS·Camilla S A Davan-WettonTrinidad Montero-Melendez
Jan 26, 2021·Expert Review of Clinical Pharmacology·Ogugua Ndili ObiRobert P Baughman
Mar 16, 2021·Frontiers in Physiology·Mingyang ChangRujun Gong
Jun 21, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Luciana P TavaresLirlândia P Sousa
May 17, 2021·Pharmacology & Therapeutics·Juliana P VagoFons A J van de Loo
Jul 27, 2021·Pediatric Neurology·Stephen AshwalChristopher G Wilson
Nov 16, 2021·Expert Opinion on Investigational Drugs·Rachel ZengJens Schmidt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

Current Drug Targets. Inflammation and Allergy
Leonard Buckbinder, Ralph P Robinson
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Sarah A MolokhiaBarbara M Wirostko
Journal of the Royal Society of Medicine
V C Neumann, K A Grindulis
© 2022 Meta ULC. All rights reserved